Chimeric Therapeutics Announces Capital Raise and Updates

Moderna Announces Advances Across Its Industry-Leading mRNA ...

Announcing a new collaboration with Carisma Therapeutics for in vivo chimeric ... announced recent updates on its industry-leading mRNA pipeline.

Chimeric Therapeutics (ASX:CHM) - Webinar Presentation

Update post interim FY24 result and capital raise. DTZ's 1H FY24 ... ABx Group have announced another significant increase to the ...

Carisma Therapeutics Reports Second Quarter 2024 Financial ...

We have also made significant progress in our in vivo oncology and fibrosis programs. The nomination of a development candidate in collaboration ...

Considerations for Academic Medical Centers Moving AHEAD

The model also strives to increase primary care investment and focus on health equity through state-based health equity plans. The model ...

ONK Therapeutics Announces $21.5M Series A Financing to ...

Galway, Ireland and San Diego, USA, 06 January 2022 – ONK Therapeutics, an innovative NK cell therapy platform company, today announced the ...

FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia

The chimeric antigen receptor T-cell therapy obecabtagene autoleucel received approval to treat patients with relapsed or refractory (R/R) B- ...

Kelonia Therapeutics Raises $50M Series A Financing

The new capital will be used to develop genetic medicines starting with an “off-the-shelf” chimeric ... City Therapeutics Announces Launch with ...

Chimeric launches Phase IB trial of glioblastoma multiforme therapy

The study intends to enrol patients at the Sarah Cannon Research Institute in Austin, Texas. ... The cell therapy is intended for the treatment of ...

Industry Updates From the Field of Stem Cell Research and ...

Orchard Therapeutics Announces additional interim results from Proof-of ... Chimeric Therapeutics completes A$4.3M seed capital raising for ground ...

CARGO Therapeutics Announces Pricing of Initial Public Offering

(“CARGO”), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients ...

Design Therapeutics Announces Business Highlights and Reports ...

Following a recent successful pre-IND meeting with the FDA, we remain on track to initiate clinical development for our FA program in the first ...

Capstan Therapeutics Announces $175M Oversubscribed Series B ...

The Series B financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, ...

Pfizer and BioNTech Announce Further Details on Collaboration to ...

Its broad portfolio of product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen ...

Chimera Investment Corporation Announces Closing of Public ...

“We believe the ability to grow our business through successful capital raising activities will benefit our shareholders over the long-term.

Hemogenyx Pharmaceuticals PLC Announces Institutional Investment

Biotech firm Hemogenyx raises £600000 through share placement to advance HEMO-CAR-T leukemia therapy into Phase I trials.

Chimeric Therapeutics (ASX:CHM) launches phase 1b glioblastoma ...

Tim McGowen: Today we're talking with Chimeric Therapeutics (ASX:CHM). Market cap of around $16m. We have with us the CEO and Managing Director, ...

Kyverna Therapeutics Extends Series B Financing Round to $145 ...

New investors, Bain Capital Life Sciences and GordonMD® Global Investments LP, join existing investors Gilead Sciences, Westlake Village ...

First Patient Enrolled in CHM CDH17 Phase 1/2 Clinical Trial | INN

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the first ...

Nature Medicine

Trauma and infections increase during war, while routine cancer care is disrupted, but telemedicine, AI chatbots and electronic health records ...

Stocks of the Hour: ENRG Elements, Chimeric Therapeutics, Marley ...

In response, Dr Jason Litten, Chief Medical Officer of Chimeric Therapeutics, “The two-part trial design also ensures that we are positioned to ...